SEC Filing Summary: ChromaDex Corporation (Form 8-K)
Business Context and Reporting Period
This Form 8-K reports the final voting results from the annual meeting of stockholders held on June 4, 2015. The registrant is ChromaDex Corporation, a Delaware corporation. Note: The input metadata references "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corporation.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders approved several key proposals at the annual meeting:
- Director Elections: All seven nominees (Frank L. Jaksch, Jr., Stephen Block, Reid Dabney, Glenn L. Halpryn, Hugh Dunkerley, Stephen Allen, and Jeff Baxter) were elected with significant majorities (approximately 66.7M to 66.9M votes "For" each).
- Authorized Share Increase: Shareholders approved an amendment to increase authorized common stock from 150,000,000 to 200,000,000 shares (65.8M For vs. 880K Against).
- Reverse Stock Split Authorization: Shareholders approved an amendment to implement a reverse stock split at a ratio between 1-for-2 and 1-for-6, effective prior to June 4, 2016 (65.9M For vs. 1.1M Against).
- Accounting Firm Ratification: Marcum, LLP was ratified as the independent registered public accounting firm for the fiscal year ending January 2, 2016 (93.4M For vs. 115K Against).
- Executive Compensation: The advisory vote on named executive officer compensation was approved (64.5M For vs. 675K Against).
- Compensation Vote Frequency: Shareholders recommended conducting future advisory votes on executive compensation every three years (42.9M votes for Three Years).
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the implementation timeline and specific ratio for the authorized reverse stock split (1-for-2 to 1-for-6).
- Confirm the impact of the increased authorized share count (200M shares) on future capital raising capabilities.
- Review the definitive proxy statement filed on April 16, 2015, for detailed context on the director nominees and executive compensation.
- Note the high volume of broker non-votes (26,583,567) across most proposals, indicating a significant portion of shares held in street name were not voted on discretionary matters.